Gemcitabine Injection, Solution
Product Images NDC 68001-342

This appears to be a product label for an injection medication called Gemcitabine. It is produced by Indian company Inias Pramacaticals Liited and distributed by BusPoit Laboratories. The medication is to be used for intravenous infusion only and must be diluted before use. Each vial contains 15 mL and 100 mg of the drug. The label includes cautionary information as well as instructions for storage and use.*

This is a prescription-only medication named Gemcitabine and it comes in a 5g/15mL solution for intravenous infusion only. It must not be refrigerated and should be kept at a temperature of 20°C - 25°C (68°F to 77°F). The batch coding is visible and it has a shelf life of 28 days. This medication is manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India. It should be diluted before use and the prescribing information should be consulted for dosage information.*

This appears to be a pharmaceutical label with information on dosing, storage, and precautions for the drug Gemcitabine, which is administered by injection. The label also includes details on the pharmaceutical company producing the drug, BluePoint Laboratories. There is a caution note indicating the drug is a cytotoxic agent. The text mentions an expiration date of 28 days after initial puncture, and advises against refrigeration.*

Gemcitabine Injection is a medication that is only available with a prescription. It is provided in a 1 9/10 mL vial containing 100 mg/mL of the active ingredient. This medication is intended for intravenous infusion only and must be diluted before use. Complete dosage and usage instructions can be found in the accompanying prescribing information. Gemcitabine Injection should be stored at Controlled Room Temperature between 20°C to 25°C (68°F to 77°F). It should not be refrigerated and must be discarded 28 days after the initial puncture. This medication is manufactured by Intas Pharmaceuticals Limited in India, under BluePoint Laboratories. It is available in a multiple dose vial.*

This is a medicine label containing information for Gemcitabine injection used for intravenous infusion only. The label includes details about its concentration, manufacture, dosage, and storage instructions. The medicine should be diluted before use and discarded after 28 days of initial puncture. The text also includes a warning about Color Agent and information about the prescribing physician's information.*

Gemcitabine is a medication used for the treatment of cancer. It is available in the form of an injection and has a strength of 200mg/2mL. The medication should be diluted before use and can only be administered intravenously. The injection comes in a blue multiple dose vial.*

This is a medication called Gemcitabine, which is an injection for intravenous infusion that comes in a bottle of 220mL size, containing 100 mg of Gemcitabine with Hydrochloride USP, Propylen Glycol, and Sodium Nitrogen. This must be diluted before use and should be discarded 28 days after puncture. The medication must be kept at room temperature and not refrigerated. The manufacturer of this medication is Intas Pharmaceuticals Limited, located in India. Keep the area blank and varnish-free for Lot and EXP identification.*

This is the prescribing information for a medication called GemCitabine, which comes in a 2/20mL vial and has to be diluted before being administered through intravenous infusion. The medication should be stored at 20°C to 25°C and cannot be refrigerated. The vial should also be discarded 28 days after the initial puncture. The manufacturer of this drug is Intas Pharmaceuticals Limited, located in Ahmedabad - India. The provided text doesn't indicate the condition being treated or the dosages for this medication.*

This is a data table showing the median time to documented disease progression for two treatments: Gemcitabine/Paclitaxel and Paclitaxel. Gemcitabine/Paclitaxel had a median time of 5.2 months, while Paclitaxel had a median time of 2.9 months. The log-rank p-value was less than 0.0001.*

This appears to be a table or chart with information on survival times for different treatments involving Gemcitabine, Cisplatin, and/or other drugs. The median survival time is specified for Gem/Cis and Cis alone, and there are columns for survival time in months for different treatments.*

This document seems to be presenting information about Gemcitabine and 5-FU, two medications used in chemotherapy treatments, and their effect on patient survival time (in months). The first lines of the document seem unrelated, consisting of individual characters and symbols.*

This is a graph that shows the progression-free survival probability of two different treatments: Gemcitabine/Carboplatin and Carboplatin alone. The graph displays a logarithmic scale, with the x-axis showing the number of months, and the y-axis showing the probability of progression-free survival. The median progression-free survival for Gemcitabine/Carboplatin is 8.6 months, whilst for Carboplatin alone, it is 5.8 months (p=0.0038).*